Search

Your search keyword '"Giri, Sanjeev"' showing total 115 results

Search Constraints

Start Over You searched for: Author "Giri, Sanjeev" Remove constraint Author: "Giri, Sanjeev"
115 results on '"Giri, Sanjeev"'

Search Results

8. P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

9. Abstract 3729: Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia

11. Abstract 1266: Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy

12. Abstract 1144: Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency

14. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies

15. Abstract 1754: First in class orally bioavailable BETBRD degraders

16. Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

17. Stability behaviour of antiretroviral drugs and their combinations. 10: LC-HRMS, LC-MSn, LC-NMR and NMR characterization of fosamprenavir degradation products and in silico determination of their ADMET properties

19. Abstract 4418: Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12

21. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay

22. Abstract 2384: Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model

23. Abstract B165: Potent selective and orally bioavailable inhibition of CDK12 by novel covalent inhibitors

24. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

25. Abstract 5108: Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines

27. Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer

28. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

29. Abstract 4798: Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL

30. A LC-MS/MS method for simultaneous estimation of a novel anti-diabetic combination of saxagliptin and dapagliflozin using a polarity switch approach: application to in vivorat pharmacokinetic studyElectronic supplementary information (ESI) available. See DOI: 10.1039/c8ay02087f

31. Abstract C191: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models

38. A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor

41. Abstract 3286: Oral bioavailability, permeability, CYP profiling, identification of major metabolites, tissue distribution and excretion profile of a novel triple kinase inhibitor, JI-101 in rats

44. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti‐cancer activity, JI‐101, in rat plasma by liquid chromatography–electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study

48. Development and validation of a liquid chromatography-tandem mass spectrometry method for quantitation of indomethacin in rat plasma and its application to a pharmacokinetic study in rats.

49. LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats.

50. Development and validation of an LC-MS/MS-ESI method for the determination of lorglumide, a CCK-1 antagonist in mouse plasma: application to a pharmacokinetic study.

Catalog

Books, media, physical & digital resources